XML 107 R94.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholders' Equity - Summary of Number of Shares Authorized to be Issued and Available for Grant (Details) - shares
Dec. 31, 2023
Jan. 31, 2023
Dec. 31, 2022
Jan. 31, 2022
Dec. 31, 2021
2017 Plan          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]          
Shares authorized to be issued 6,330,713,000   5,140,112,000   3,944,750,000
Shares available for grant 662,662,000 [1] 1,189,801 367,243,000 [1] 1,185,112 23,153,000 [1]
2013 Plan          
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]          
Shares authorized to be issued 2,036,219,000   2,037,019,000   2,047,269,000
[1] In January 2023 and January 2022 the Board of Directors ratified the addition of 1,189,801 and 1,185,112 shares of common stock, respectively, to the number of shares available for issuance under the 2017 Plan pursuant to the annual increase provision of such plan. Unless the Board of Directors determines otherwise, additional annual increases will be effective on each January 1, through January 1, 2027. The 2017 Plan permits the company to settle awards, if and when vested, in cash at its discretion. Pursuant to the terms of the 2017 Plan, the number of shares authorized for issuance thereunder will only be reduced with respect to shares of common stock actually issued upon exercise or settlement of an award. Shares of common stock subject to awards that have been canceled, expired, forfeited or otherwise not issued under an award and shares of common stock subject to awards settled in cash do not count as shares of common stock issued under the 2017 Plan. The Company expects to have sufficient shares available under the 2017 Plan to satisfy the future settlement of outstanding awards. Shares reserved for future issuance include 3,000,000 shares underlying the 3,000,000 performance stock appreciation rights granted in December 2021 that are subject to vesting based on the achievement of certain market conditions. Assuming achievement at the highest price performance hurdle, approximately 2,000,000 shares of common stock would be issued upon vesting of these performance SARs. To date, none of the market conditions have been achieved. Shares available for grant exclude these awards of stock appreciation rights approved in December 2021 that are subject to vesting based on the achievement of certain market conditions. To date, none of the market conditions, have been, and they may not be, achieved. See footnote 1 to the table in Common Stock Reserved for Future Issuance below for additional information on stock appreciation rights.